Livio Trentin

Has grant

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

HSP70-HSF1 interplay in Chronic Lymphocytic Leukemia as a new druggable target

Open Date: 2018-01-01

Close Date: 2018-12-01

Grant: Close

Overcome Ibrutinib resistance in B-cell lymphoproliferative diseases

Open Date: 2017-01-01

Close Date: 2018-12-01

Grant: Close

Investigation of Signaling Transduction Pathways in Chronic Lymphocytic Leukemia to Define New Targets for Therapy

Open Date: 2015-01-01

Close Date: 2017-12-01

Grant: Close

Lyn Signaling Pathway Molecules as new Targets for Therapy in Chronic Lymphocytic Leukemia

Open Date: 2015-01-01

Close Date: 2016-12-01

Grant: Close

SIGNALING MOLECULES AS NEW TARGETS FOR THERAPY IN LYMPHOPROLIFERATIVE DISORDERS

Open Date: 2012-01-01

Close Date: 2013-12-01

Articles (11)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Assistant Professor of Hematology

Università degli Studi della Campania Luigi Vanvitelli Scuola di Medicina e Chirurgia

ITALY

View details

Candida VITALE

University of Turin

ITALY

View details

Annalisa Angelini

University of Padua

ITALY

View details

Andrea Visentin

Assistant professor

University of Padua

ITALY

View details

Francesco Angotzi

University of Padua

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Livio Trentin

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (11)

Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature

Focal adhesion kinase activation by calcium‐dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness

Antibody Response to the SARS-CoV-2 Vaccine and COVID-19 Vulnerability during the Omicron Pandemic in Patients with CLL: Two-Year Follow-Up of a Multicenter Study

Higher accuracy of surgical over core needle biopsy for the diagnosis of lymphoproliferative disorders

Is It Still Possible to Think about HSP70 as a Therapeutic Target in Onco-Hematological Diseases?

Chest pain in cardiac amyloidosis: occurrence, causes and prognostic significance.

DNA-Interactive and Damage Study with <i>meso</i>-Tetra(2-thienyl)porphyrins Coordinated with Polypyridyl Pd(II) and Pt(II) Complexes.

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

Pro-inflammatory cells sustain leukemic clonal expansion in T-cell large granular lymphocyte leukemia.

BTK and PLCG2 remain unmutated in one third of patients with CLL relapsing on ibrutinib.

The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies

Collaborators (12)

Federica Frezzato

LARA MUSSOLIN

Francesca Romana Mauro

Giulio Sinigiani

Marta COSCIA

PAOLO SPORTOLETTI

Giuseppe Maggioni

Francesco Piazza

Candida VITALE

Annalisa Angelini

Andrea Visentin

Francesco Angotzi

Make your next move.